- Home
- BTMWW vs RLAY Comparison
BTMWW vs RLAY Comparison
Compare BTMWW & RLAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BTMWW | RLAY |
|---|---|---|
| Founded | N/A | 2015 |
| Country | United States | United States |
| Employees | 126 | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | 1.3B |
| IPO Year | 2022 | 2020 |
Fundamental Metrics
Financial Performance| Metric | BTMWW | RLAY |
|---|---|---|
| Price | $0.14 | $8.01 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $16.00 |
| AVG Volume (30 Days) | N/A | ★ 2.0M |
| Earning Date | N/A | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $8,355,000.00 |
| Revenue This Year | N/A | $20.47 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | N/A | $1.78 |
| 52 Week High | N/A | $8.70 |
Technical Indicators
Market Signals| Indicator | BTMWW | RLAY |
|---|---|---|
| Relative Strength Index (RSI) | 42.22 | 63.19 |
| Support Level | $0.12 | $7.42 |
| Resistance Level | $0.15 | $8.00 |
| Average True Range (ATR) | 0.03 | 0.52 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 63.50 | 65.26 |
Price Performance
Historical ComparisonAbout BTMWW Bitcoin Depot Inc. Warrant
Bitcoin Depot Inc owns and operates the widest network of BTMs across North America where customers can buy and sell Bitcoin. Bitcoin Depot helps power the digital economy for users of cash. It has locations across the U.S. and Canada at, among others, the following types of retailers: Convenience Stores and Gas Station Chains, Pharmacies and Grocers and Mall Operators.
About RLAY Relay Therapeutics Inc.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).